证券代码：300436 证券简称：广生堂 公告编号：2023073 福建广生堂药业股份有限公司 关于第四届董事会第二十四次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 福建广生堂药业股份有限公司（以下简称"公司"）第四届董事会第二十四次 会议于 2023 年 8 月 18 日以邮件、电话等形式发出通知，于 2023 年 8 月 28 日在 福建省福州市闽侯县福州高新区乌龙江中大道 7 号海西高新技术产业园创新园 二期 16 号楼 13F 会议室以通讯表决方式召开。会议由董事长李国平先生主持， 会议应到董事 8 人，实到董事 8 人，监事会成员列席了会议。会议的召开符合《公 司法》和《公司章程》的规定。 二、董事会会议审议情况 （一）审议通过《关于<2023 年半年度报告>及其摘要的议案》 本议案以 8 票同意、0 票反对、0 票弃权的表决结果审议通过。 公司独立董事就该事项发表了同意的独立意见。 具体内容详见公司披露于巨潮资讯网（http://www.cninfo.com.cn）的《2023 年半年度募集资金存放与使用 ...

福建广生堂药业股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 一、 募集资金基本情况 经中国证券监督管理委员会证监许可[2020]2748 号核准，并经深圳证券交易所同意，本 公司由主承销商中信证券股份有限公司于 2021 年 6 月向特定对象发行普通股（A 股）股票 1,877.70 万股，每股面值 1 元，每股发行价人民币 27.40 元。截至 2021 年 6 月 21 日止，本 公司共募集资金 514,489,800.00 元，扣除发行费用（不含税）14,905,660.38 元，募集资金净 额 499,584,139.62 元。 截止 2021 年 6 月 21 日，上述募集资金已全部到位，业经大华会计师事务所（特殊普通 合伙）以"大华验字[2021]000437 号"验资报告验证确认。 截止 2023 年 6 月 30 日，公司对募集资金项目累计投入 374,706,446.42 元，其中：公司 于募集资金到位之前利用自有资金先期投入募集资金项目人民币 53,166,737.48 元；2021 年 6 月 21 日至 2022 年 12 月 31 日止使用募集资金人民币 370, ...

证券代码：300436 证券简称：广生堂 公告编号：2023074 一、监事会会议召开情况 福建广生堂药业股份有限公司（以下简称"公司"）第四届监事会第二十二 次会议于 2023 年 8 月 18 日以邮件、电话等形式发出通知，于 2023 年 8 月 28 日在福建省福州市闽侯县福州高新区乌龙江中大道 7 号海西高新技术产业园创 新园二期 16 号楼 13F 会议室以通讯表决方式召开。会议由监事会主席主持，会 议应到监事 3 人，实到监事 3 人，3 名监事全部参与了表决。会议的召开符合《公 司法》和《公司章程》的规定。 福建广生堂药业股份有限公司 关于第四届监事会第二十二次会议决议的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 二、监事会会议审议情况 （一）审议通过《关于<2023 年半年度报告>及其摘要的议案》 经审核，监事会认为：董事会编制的《2023 年半年度报告》及其摘要的程 序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映 了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 本议案以 3 票同意，0 票反 ...

| 非经营性 | | 占用方与上市公司 | 上市公司核算 | 2023年期初占用 | 2023年半年度占用 | 2023年半年度占 | 2023年半年度偿还 | 2023年半年度期末 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 资金占用 | 资金占用方名称 | 的关联关系 | 的会计科目 | 资金余额 | 累计发生金额 （不含利息） | 用资金的利息 （如有） | 累计发生金额 | 占用资金余额 | 占用形成原因 | 占用性质 | | 控股股东、实际控制人 及其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | | | | | | | | | | — | | 前控股股东、实际控制 人及其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | | | | | | | | | | — | | 其他关联方及其附属企 业 | | | | | | | | | | 非经营性占用 | | 小计 | | | | | | | | | | | | 总计 | | | | ...

公司于近日收到控股股东奥华集团出具的《股份减持计划告知函》。现将具 体情况公告如下： 一、股东基本情况 1、股东名称：福建奥华集团有限公司，公司控股股东。 2、持股情况：持有公司股份 35,068,651 股，占公司总股本的 22.02%。一致 行动人奥华集团、李国平先生、叶理青女士、李国栋先生及福建平潭奥泰科技投 资中心（有限合伙）合计持有公司股份 73,131,292 股，占公司总股本的 45.92%。 二、本次减持计划的主要内容 证券代码：300436 证券简称：广生堂 公告编号：2023071 福建广生堂药业股份有限公司 关于控股股东减持股份的预披露公告 股东福建奥华集团有限公司保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。本公司及董事会全体成员保证公告内容 与信息披露义务人提供的信息一致。 特别提示： 持有福建广生堂药业股份有限公司（简称"公司"或"广生堂"）股份 35,068,651 股（占本公司总股本比例 22.02%）的控股股东福建奥华集团有限公司 （简称"奥华集团"）计划以集中竞价方式及大宗交易方式减持本公司股份不超 过 4,778,010 股（占本公司总 ...

3、请董秘回复下 161 的进展，还有没有二期？ 尊敬的投资者，您好！新型 c-Met 靶向药物 GST-HG161 项 目已完临床 I 期试验剂量递增阶段所有受试者的耐受性和安全 性观察，总体安全性良好，目前正在进行 Ib 期多中心扩展阶段 试验，将积极推进争取早日开展 II 期临床研究，后续进展敬请 关注公司公告！谢谢！ 4、h171 的成本会是多少钱？h171 需要多长时间申请上市？ 证券代码：300436 证券简称：广生堂 福建广生堂药业股份有限公司投资者关系活动记录表 编号：2023-002 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | □ 新闻发布会 □ 路演活动 | | | 现场参观 □ | | | 其他 （请文字说明其他活动内容） □ | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 15 日 (周一) 上午 09:00~17:30 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采 ...

1 证券代码：300436 证券简称：广生堂 公告编号：2023050 福建广生堂药业股份有限公司 关于参加福建辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，福建广生堂药业股份有限公司（以下简 称"公司"） 将参加由福建证监局、福建省上市公司协会与深圳市全景网络有 限公司联合举办的"2023 年福建辖区上市公司投资者网上集体接待日活动"， 现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP, 参 与本次互动交流，活动时间为 2023 年 5 月 15 日（周一）16:00-17:30。届时公司 高管将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广 大投资者踊跃参与！ 特此公告！ 福建广生堂药业股份有限公司董事会 2023 年 5 月 11 日 ...

股票代码：300436 股票简称：广生堂 福建广生堂药业股份有限公司投资者关系活动记录表 编号：2023-001 | 投资者关系活动类别 | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 √业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 线上参与公司广生堂 2022 年度网上业绩说明会的投资者 | | 时间 | 2023 年 04 月 27 日（星期四）下午 15:00-17:00 | | 地点 | "广生堂投资者关系"微信小程序 | | 上市公司接待人员姓名 | 公司董事长、总经理：李国平先生 | | | 独立董事：任红先生 | | | 董事、副总经理、董事会秘书：林晓辉先生 | | | 财务总监：官建辉先生 | | | 保荐代表人：吴文杰先生 | | | 1、问：请详细介绍一下贵公司的战略规划 答：尊敬的投资者，您好！未来公司将秉持"精益主动、创新超 越"的战略理念，努力实现高质量、跨越式发展。公司将坚定实 | | | 施创新发展战略，持续提升创新投入，加快推进 ...

Financial Performance - The company's operating revenue remained stable compared to the previous year, but it reported a net loss due to increased R&D expenses of RMB 185.46 million, an increase of RMB 116.47 million year-on-year[5]. - The loss was primarily attributed to the ongoing impact of national drug procurement policies, which led to a decrease in sales revenue and gross profit for antiviral products[6]. - The company will not distribute cash dividends or issue bonus shares for the year[9]. - The net profit attributable to shareholders was -¥127,403,884.79, a decrease of 265.19% from -¥34,886,550.27 in the previous year[25]. - The basic earnings per share for 2022 was -¥0.8004, down 242.78% from -¥0.2335 in 2021[25]. - The net cash flow from operating activities was -¥119,679,687.02, a decline of 573.69% compared to -¥17,764,779.27 in 2021[25]. - The company reported a quarterly operating revenue of ¥96,523,364.67 in Q1 2022, with a decline to ¥88,298,732.06 in Q4 2022[28]. - The net profit attributable to shareholders for Q4 2022 was -¥55,910,815.44, worsening from -¥45,270,492.49 in Q3 2022[28]. - The company’s weighted average return on equity was -12.87% in 2022, down from -4.40% in 2021[25]. - The total net assets attributable to shareholders decreased by 11.01% to ¥928,462,440.88 at the end of 2022 from ¥1,043,355,057.64 at the end of 2021[25]. Research and Development - The company plans to continue investing in innovative drug research and development, with a focus on accelerating the progress of six global innovative drug projects[6]. - The R&D expenses for the year were RMB 185.46 million, reflecting a significant investment in innovation despite short-term losses[5]. - The company invested a total of 185.46 million yuan in R&D in 2022, an increase of 116.47 million yuan year-on-year, with 109.03 million yuan specifically allocated to the development of GST-HG171[94]. - The innovative drug GST-HG171 is currently in a seamless II/III phase clinical trial and is expected to be approved for market launch within the year, marking a significant breakthrough for the company[88]. - The company is developing innovative hepatitis B drugs GST-HG141 and GST-HG131, with GST-HG141 entering Phase II trials and GST-HG131 being the first HBsAg inhibitor approved for clinical trials in China[77][78]. - The company has established a comprehensive product line in liver health, including five major antiviral drugs for hepatitis B, positioning itself as a leading enterprise in this field[89]. - The company has made significant progress in its R&D pipeline, with multiple projects in various stages of clinical trials, including GST-HG171, which is currently advancing to II/III phase trials[83]. Market and Industry Trends - The pharmaceutical industry is expected to maintain an annual revenue and profit growth rate of over 8% during the 14th Five-Year Plan period, with the added value accounting for about 5% of total industry output[38]. - The market for hepatitis B virus drugs in China is projected to grow to 72.33 billion yuan by 2030, with an expected annual compound growth rate of 35.8% from 2025 to 2030[41]. - The global market for drugs targeting NASH is expected to exceed $15 billion by 2025, indicating significant market potential[46]. - The pharmaceutical industry is experiencing increased pressure due to various regulatory policies, but innovation is becoming the main theme for future growth opportunities[38]. - The company has developed into a well-known enterprise in the domestic antiviral field, particularly in hepatitis B virus treatment, with five major antiviral drugs including Adefovir, Lamivudine, Entecavir, Tenofovir, and Prodrug Tenofovir[56]. Strategic Initiatives - Future strategies include strengthening brand strategy, international expansion, and enhancing the integrated supply and sales system[7]. - The company is actively pursuing potential mergers and acquisitions to enhance its market share and operational capabilities[172]. - The company is focusing on expanding its product pipeline with high-end generic drugs, which will support steady revenue growth in the future[89]. - The company aims to enhance its market competitiveness in the hepatitis treatment field with innovative drug candidates like GST-HG121 and GST-HG131[83]. - The company is actively implementing an innovation development strategy, collaborating with leading global innovative drug research and development enterprises to develop multiple first-in-class innovative drugs targeting antiviral, hepatitis B clinical cure, anti-liver cancer, and anti-liver fibrosis[56]. Corporate Governance and Management - The company has established a transparent performance evaluation and incentive mechanism for directors and senior management, with plans to implement stock option incentive plans in the future[163]. - The company has implemented governance practices in compliance with relevant laws and regulations, ensuring independent operations of the board and management[157]. - The company has a clear and independent corporate governance structure, with no interference from shareholders in operational responsibilities[166]. - The company has established independent financial management and internal audit departments, ensuring independent financial decision-making[166]. - The management team has extensive experience in pharmaceutical development and operations, with key leaders having over 20 years of industry experience[93]. Human Resources and Employee Development - The company has established an employee incentive system to attract and retain core talent, including various subsidies and bonuses[195]. - The newly established Guangshengtang Academy aims to develop pharmaceutical talents with a national and international perspective[196]. - The company emphasizes the importance of human resources and has implemented a comprehensive talent development and training system[196]. - In 2022, the company conducted a total of 374 training sessions, with 1,391 hours of training and 4,141 participants[197]. - The total number of employees at the end of the reporting period is 908, with 549 from the parent company[193]. Risk Management - The company faces risks from industry policy changes and intensified market competition, which could impact sales regions and pricing strategies[142][144]. - The company emphasizes the importance of retaining core technical personnel to maintain its competitive edge in drug development and innovation[146]. - The company is focused on mitigating risks associated with new drug development and market acceptance, ensuring robust marketing strategies for new products[145][147].

Financial Performance - The company's revenue for Q1 2023 was ¥88,231,089.07, a decrease of 8.59% compared to ¥96,523,364.67 in the same period last year[5] - The net loss attributable to shareholders was ¥63,308,377.66, representing a significant decline of 593.29% from a loss of ¥9,131,629.17 in the previous year[5] - The company's basic and diluted earnings per share were both -¥0.3975, a decrease of 591.30% from -¥0.0575 in the same period last year[5] - The net profit for the first quarter was a loss of ¥70,563,194.81, compared to a loss of ¥11,085,643.29 in the same period last year, indicating a substantial decline[30] - The total comprehensive loss for the first quarter was ¥70,563,194.81, compared to a loss of ¥11,085,643.29 in the previous period[30] Cash Flow and Liabilities - The net cash flow from operating activities was -¥118,514,024.25, a decline of 513.17% compared to -¥19,328,170.43 in the same period last year[5] - The company's total liabilities amounted to approximately 834.06 million RMB, up from 539.22 million RMB, indicating a significant increase in financial obligations[26] - The company's cash and cash equivalents increased to approximately 329.41 million RMB from 238.98 million RMB, reflecting a growth of about 37.8%[24] - Cash and cash equivalents at the end of the period totaled ¥325,376,744.13, down from ¥358,510,329.59 at the end of the previous period[33] - Financing activities generated a net cash inflow of ¥301,181,831.14, compared to ¥52,245,691.70 in the previous period, indicating improved financing conditions[33] Research and Development - R&D expenses increased by 82.92% to ¥47,267,500, primarily due to ongoing investments in innovative drug development[8] - Research and development expenses rose significantly to ¥47,267,518.06, compared to ¥25,840,978.81 in the previous period, reflecting a 83.5% increase[27] - The company is advancing the clinical trial of its antiviral drug GST-HG171, which has shown superior efficacy compared to Pfizer's Paxlovid in early trials[17] - The clinical trial for the hepatitis B drug GST-HG141 has entered a new phase, with the first subject successfully enrolled in the Phase II trial[18] - The company is conducting a key Phase II/III registration clinical trial for GST-HG171 in collaboration with major hospitals[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,063[12] - The largest shareholder, Fujian Aohua Group, holds 22.02% of shares, amounting to 35,068,651 shares, with 21,610,000 shares pledged[12] - The second-largest shareholder, Ye Liqing, holds 8.50% of shares, totaling 13,536,700 shares, with 10,152,525 shares under lock-up[12] - The third-largest shareholder, Li Guoping, holds 6.63% of shares, amounting to 10,560,866 shares, with 7,920,649 shares under lock-up[12] - The company has not disclosed any other shareholder relationships beyond those mentioned, nor any additional shareholders that may be considered as acting in concert[14] Assets and Investments - Total assets at the end of the reporting period were ¥1,719,115,113.73, an increase of 15.00% from ¥1,494,844,681.01 at the end of the previous year[5] - The company reported a significant increase in long-term borrowings, which rose by 120.54% to ¥18,533,710.00, primarily due to new bank loans[9] - The company's inventory rose to approximately 79.61 million RMB from 68.66 million RMB, showing an increase of about 15.5%[24] - The company reported a significant increase in construction in progress, rising to approximately 90.61 million RMB from 50.60 million RMB, indicating ongoing investment in development projects[25] - The company is actively expanding its production capabilities, with significant investments in the construction of a new manufacturing facility for oral dosage forms[9] Other Financial Activities - The cash flow from financing activities was ¥30,118,180.00, an increase of 476.47% compared to ¥5,224,570.00 in the previous year[10] - The company initiated a new round of refinancing on March 3, 2023, to enhance funding sources for innovative drug research and development, aiming to accelerate the development process and improve future profitability[20] - Guangsheng Zhonglin completed a financing of 220 million RMB, with 38.5 million RMB added to registered capital and 181.5 million RMB to capital reserves, reducing the company's shareholding from 90% to 81.0811%[19] - The controlling shareholder, Aohua Group, pledged 5 million shares and an additional 500,000 shares, with total pledged shares amounting to 26.79 million, representing 35.87% of their holdings and 16.82% of total shares[22]